Rationales of Cold Plasma Jet Therapy in Skin Cancer
Experimental Dermatology · 2025-02 · 34 (2)
DOI: 10.1111/exd.70063 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Experimental Dermatology, online erschienen am 19.02.2025. Verfasst von Sander Bekeschus und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venerology, Rostock University Medical Center, Rostock, Germany. Hauptthemen laut MEDLINE: Skin Neoplasms, Plasma Gases, Melanoma, Basal Cell Carcinoma. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Skin cancer affects millions of patients worldwide, and its incidence is increasing. Current therapies targeting skin tumour subtypes, such as basal cell carcinoma, cutaneous squamous cell carcinoma, melanoma and actinic keratosis, vary in their degree of effectiveness and tolerability, motivating new research avenues on complementing treatment strategies. Cold medical gas plasma is a partially ionised gas operated at about body temperature and generates various reactive oxygen and nitrogen species simultaneously. A range of medical gas plasma devices has proven safe in thousands of patients and is an approved medical product for dermatology conditions, such as nonhealing wounds, in Europe and, more broadly, for clinical trials. Extending potential gas plasma applications in the field of dermato‐oncology is therefore plausible, especially in light of the strong preclinical evidence and early clinical data. This review summarises existing work on gas plasma treatment, focusing on approved jet plasmas in skin cancer and outlining central mechanisms and treatment concepts. It also provides a concrete perspective on integrating medical gas plasma treatment into existing skin cancer therapy schemes, encouraging translational scientists and clinicians to enable gas plasma‐assisted cancer care through clinical research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venerology, Rostock University Medical Center, Rostock, Germany.
- ZIK Plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Greifswald, Germany.
- Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
- neoplas MED, Greifswald, Germany.
- School of Chemistry and Physics and Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, Queensland, Australia.
- School of Biomedical Sciences and Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Queensland, Australia.
Zitieren
APA
Bekeschus, S., Singer, D., Ratnayake, G., Ruhnau, K., Ostrikov, K., & Thompson, E. W. (2025). Rationales of Cold Plasma Jet Therapy in Skin Cancer. Experimental Dermatology, 34(2). https://doi.org/10.1111/exd.70063
Vancouver
Bekeschus S, Singer D, Ratnayake G, Ruhnau K, Ostrikov K, Thompson EW. Rationales of Cold Plasma Jet Therapy in Skin Cancer. Experimental Dermatology. 2025;34(2). doi:10.1111/exd.70063
BibTeX
@article{Bekeschus2025,
author = {Bekeschus, Sander and Singer, Debora and Ratnayake, Gishan and Ruhnau, Klaus and Ostrikov, Kostya and Thompson, Erik W},
title = {Rationales of Cold Plasma Jet Therapy in Skin Cancer},
journal = {Experimental Dermatology},
year = {2025},
volume = {34},
number = {2},
doi = {10.1111/exd.70063}
}
EUVIMED